The Commodity Futures Trading Commission on Friday approved KalshiEX LLC's BTCPERP contract — a no-expiry bitcoin perpetual futures contract tied to spot BTC price — and separately issued a no-action position letting Coinbase Financial Markets treat certain Deribit digital commodity derivatives as foreign futures. The moves mark the first formal U.S. regulatory green light for a bitcoin perpetual product and a narrower pathway for institutional access to crypto derivatives that have long been unavailable to U.S. customers.
Two different paths to market
The Kalshi approval came as a formal Commission order under Section 5c(c)(4) of the Commodity Exchange Act and Regulation 40.3. The Coinbase relief is staff-level, fact-specific, and nonbinding — not a product approval. CFTC Chairman Mike Selig said the Kalshi order delivers on his pledge to onshore crypto asset perpetuals. Coinbase CEO Brian Armstrong noted that until now, U.S. users were locked out of about 80% of global crypto markets.
Timeline and conditions
Kalshi submitted its contract on May 28, according to the order, though the CFTC's release references a May 29 submission. The approval itself is dated May 29. Coinbase said institutional onboarding can begin now: options on Deribit are already live through CFM, and perpetual futures will follow. Broader retail access is expected later, the exchange stated.
Michael Saylor tied the CFTC's guidance directly to Bitcoin holders and MicroStrategy's Bitcoin-backed credit strategy. The timing isn't accidental — the regulator has been under pressure to open up U.S. access to products that dominate global crypto trading volume. Coinbase's relief is limited but gives institutional clients a legal route to trade Deribit contracts without leaving U.S. jurisdiction.
Coinbase said perpetual futures will follow, though broader retail access isn't expected until later. The CFTC's Kalshi order is effective immediately, meaning the exchange can begin listing the contract. Whether other exchanges will seek similar approvals — or challenge the scope of the no-action relief — remains an open question.
